Grifols' ongoing commitment
Throughout the COVID-19 pandemic, Grifols has continued to prioritize the health and safety of our employees, who in turn are ensuring the production of vital plasma-derived medicines for patients.
In line with our values and mission, our work for society during these exceptional times has contributed significantly to advance the understanding of the potential of plasma therapies to treat COVID-19 patients in various stages of the disease.
Grifols has an ongoing collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate further into how plasma from people who have already recovered from the infection – known as convalescent plasma – might treat the SARS-CoV-2 coronavirus.
Other relevant research initiatives underway include a promising study by the company Biotest, in which we have invested, to treat severely ill COVID-19 patients with an immunoglobulin concentrate called trimodulin.
The company also developed in record time a highly sensitive molecular test based on TMA (transcription-mediated amplification) technology to facilitate early detection of the coronavirus. This enabled the fast ramp up of testing capabilities during the initial outbreaks.
Grifols also supports various external research programs as well, such as a collaboration with the consortium IrsiCaixa, Barcelona Supercomputing Center (BSC) and the Institute of Agri-Food Research and Technology (IRTA-CReSA) on the identification of prototype vaccines and antibody therapies for SARS-CoV-2.
“As always, we remain deeply committed to applying our experience and resources to continue the fight against this public health crisis.”